Compare Danaher Corporation (DHR) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Tesla, Inc. — how do they compare? Danaher Corporation trades at $204.04 (market cap $145.83B), while Tesla, Inc. trades at $327.91 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 9× Danaher Corporation's market cap, and Danaher Corporation pays a 0.77% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| DHR | TSLA | |
|---|---|---|
Market Cap | $145.83B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $489.88 |
52-Week Low | $161.91 | $298.16 |
Enterprise Value | $168.04B | $1.29T |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Tesla (TSLA) trades at $330.87, up 0.7% on the day, with a bearish technical signal from moving averages and a mixed fundamental picture. The stock shows high valuation multiples (P/E 308.16, P/S 11.36) amid declining profitability, with net income margin falling to 3.67% in 2025 from 15.49% in 2023. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, but Q2 2026 earnings missed expectations.
Outlook remains polarized: analyst consensus price target of $393.87 suggests 19% upside, but high valuation and margin compression pose risks. Key catalysts include autonomy advancements and energy/robotics growth, while competition and execution challenges weigh on sentiment. The stock's trajectory hinges on delivering AI-driven revenue streams beyond automotive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
